nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—VEGFA—atherosclerosis	0.291	0.788	CbGaD
Vandetanib—ALB—atherosclerosis	0.0782	0.212	CbGaD
Vandetanib—ABCC1—Rosuvastatin—atherosclerosis	0.0645	0.244	CbGbCtD
Vandetanib—ABCG2—Rosuvastatin—atherosclerosis	0.0431	0.163	CbGbCtD
Vandetanib—ABCG2—Ezetimibe—atherosclerosis	0.0431	0.163	CbGbCtD
Vandetanib—ABCG2—Pravastatin—atherosclerosis	0.0392	0.149	CbGbCtD
Vandetanib—ALB—Rosuvastatin—atherosclerosis	0.0297	0.113	CbGbCtD
Vandetanib—CYP3A4—Rosuvastatin—atherosclerosis	0.00932	0.0353	CbGbCtD
Vandetanib—CYP3A4—Ezetimibe—atherosclerosis	0.00932	0.0353	CbGbCtD
Vandetanib—CYP3A4—Simvastatin—atherosclerosis	0.00866	0.0328	CbGbCtD
Vandetanib—CYP3A4—Lovastatin—atherosclerosis	0.00848	0.0321	CbGbCtD
Vandetanib—CYP3A4—Pravastatin—atherosclerosis	0.00848	0.0321	CbGbCtD
Vandetanib—STK10—renal artery—atherosclerosis	0.00793	0.0993	CbGeAlD
Vandetanib—KDR—umbilical vein—atherosclerosis	0.00246	0.0308	CbGeAlD
Vandetanib—KDR—hindlimb—atherosclerosis	0.00225	0.0282	CbGeAlD
Vandetanib—KDR—appendage—atherosclerosis	0.00193	0.0242	CbGeAlD
Vandetanib—FLT4—endothelium—atherosclerosis	0.00178	0.0222	CbGeAlD
Vandetanib—RIPK2—endothelium—atherosclerosis	0.00177	0.0221	CbGeAlD
Vandetanib—TEK—artery—atherosclerosis	0.00169	0.0212	CbGeAlD
Vandetanib—FLT4—blood vessel—atherosclerosis	0.00164	0.0205	CbGeAlD
Vandetanib—RIPK2—blood vessel—atherosclerosis	0.00163	0.0204	CbGeAlD
Vandetanib—SRC—artery—atherosclerosis	0.0015	0.0188	CbGeAlD
Vandetanib—Bosutinib—CSF1R—atherosclerosis	0.00147	0.716	CrCbGaD
Vandetanib—TEK—endothelium—atherosclerosis	0.00143	0.0179	CbGeAlD
Vandetanib—KDR—artery—atherosclerosis	0.00138	0.0173	CbGeAlD
Vandetanib—TEK—blood vessel—atherosclerosis	0.00132	0.0165	CbGeAlD
Vandetanib—SRC—endothelium—atherosclerosis	0.00127	0.0159	CbGeAlD
Vandetanib—SRC—blood vessel—atherosclerosis	0.00117	0.0147	CbGeAlD
Vandetanib—KDR—endothelium—atherosclerosis	0.00117	0.0146	CbGeAlD
Vandetanib—TYRO3—connective tissue—atherosclerosis	0.00109	0.0136	CbGeAlD
Vandetanib—LYN—connective tissue—atherosclerosis	0.00108	0.0135	CbGeAlD
Vandetanib—KDR—blood vessel—atherosclerosis	0.00108	0.0135	CbGeAlD
Vandetanib—PDGFRB—blood vessel—atherosclerosis	0.000931	0.0117	CbGeAlD
Vandetanib—FLT3—connective tissue—atherosclerosis	0.000924	0.0116	CbGeAlD
Vandetanib—RIPK2—connective tissue—atherosclerosis	0.000835	0.0105	CbGeAlD
Vandetanib—BMPR1B—adipose tissue—atherosclerosis	0.000817	0.0102	CbGeAlD
Vandetanib—FLT3—cardiovascular system—atherosclerosis	0.000804	0.0101	CbGeAlD
Vandetanib—ERBB3—connective tissue—atherosclerosis	0.000799	0.01	CbGeAlD
Vandetanib—RET—connective tissue—atherosclerosis	0.000741	0.00928	CbGeAlD
Vandetanib—AXL—connective tissue—atherosclerosis	0.000738	0.00925	CbGeAlD
Vandetanib—FLT4—cardiovascular system—atherosclerosis	0.00073	0.00915	CbGeAlD
Vandetanib—RIPK2—cardiovascular system—atherosclerosis	0.000726	0.0091	CbGeAlD
Vandetanib—STK35—adipose tissue—atherosclerosis	0.000695	0.0087	CbGeAlD
Vandetanib—FYN—connective tissue—atherosclerosis	0.000691	0.00866	CbGeAlD
Vandetanib—ABL2—adipose tissue—atherosclerosis	0.000677	0.00848	CbGeAlD
Vandetanib—TEK—connective tissue—atherosclerosis	0.000675	0.00846	CbGeAlD
Vandetanib—EGFR—adipose tissue—atherosclerosis	0.000661	0.00828	CbGeAlD
Vandetanib—MKNK1—cardiovascular system—atherosclerosis	0.000653	0.00818	CbGeAlD
Vandetanib—FGR—cardiovascular system—atherosclerosis	0.000645	0.00808	CbGeAlD
Vandetanib—FLT4—adipose tissue—atherosclerosis	0.000644	0.00807	CbGeAlD
Vandetanib—AXL—cardiovascular system—atherosclerosis	0.000642	0.00805	CbGeAlD
Vandetanib—RIPK2—adipose tissue—atherosclerosis	0.00064	0.00803	CbGeAlD
Vandetanib—VEGFA—adipose tissue—atherosclerosis	0.000639	0.008	CbGeAlD
Vandetanib—FMO1—adipose tissue—atherosclerosis	0.000635	0.00796	CbGeAlD
Vandetanib—IRAK4—adipose tissue—atherosclerosis	0.000625	0.00784	CbGeAlD
Vandetanib—YES1—connective tissue—atherosclerosis	0.000623	0.00781	CbGeAlD
Vandetanib—ERBB3—adipose tissue—atherosclerosis	0.000613	0.00768	CbGeAlD
Vandetanib—FYN—cardiovascular system—atherosclerosis	0.000601	0.00753	CbGeAlD
Vandetanib—SRC—connective tissue—atherosclerosis	0.0006	0.00751	CbGeAlD
Vandetanib—TEK—cardiovascular system—atherosclerosis	0.000587	0.00736	CbGeAlD
Vandetanib—LYN—liver—atherosclerosis	0.000582	0.00729	CbGeAlD
Vandetanib—MKNK1—adipose tissue—atherosclerosis	0.000576	0.00721	CbGeAlD
Vandetanib—LCK—adipose tissue—atherosclerosis	0.000569	0.00712	CbGeAlD
Vandetanib—FGR—adipose tissue—atherosclerosis	0.000569	0.00712	CbGeAlD
Vandetanib—AXL—adipose tissue—atherosclerosis	0.000566	0.0071	CbGeAlD
Vandetanib—KDR—connective tissue—atherosclerosis	0.000552	0.00691	CbGeAlD
Vandetanib—FMO3—adipose tissue—atherosclerosis	0.000549	0.00688	CbGeAlD
Vandetanib—SLK—adipose tissue—atherosclerosis	0.000545	0.00683	CbGeAlD
Vandetanib—STK10—cardiovascular system—atherosclerosis	0.000537	0.00674	CbGeAlD
Vandetanib—FYN—adipose tissue—atherosclerosis	0.00053	0.00664	CbGeAlD
Vandetanib—Haematuria—Rosuvastatin—atherosclerosis	0.000523	0.00474	CcSEcCtD
Vandetanib—SRC—cardiovascular system—atherosclerosis	0.000522	0.00654	CbGeAlD
Vandetanib—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.000521	0.00473	CcSEcCtD
Vandetanib—Influenza—Lovastatin—atherosclerosis	0.000521	0.00473	CcSEcCtD
Vandetanib—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.000518	0.0047	CcSEcCtD
Vandetanib—TEK—adipose tissue—atherosclerosis	0.000518	0.00649	CbGeAlD
Vandetanib—MAP4K5—adipose tissue—atherosclerosis	0.000518	0.00649	CbGeAlD
Vandetanib—Gastrointestinal haemorrhage—Niacin—atherosclerosis	0.000518	0.0047	CcSEcCtD
Vandetanib—Sinusitis—Rosuvastatin—atherosclerosis	0.000514	0.00466	CcSEcCtD
Vandetanib—Influenza—Ezetimibe—atherosclerosis	0.000511	0.00464	CcSEcCtD
Vandetanib—Pancreatitis—Lovastatin—atherosclerosis	0.000511	0.00463	CcSEcCtD
Vandetanib—Pancreatitis—Ezetimibe—atherosclerosis	0.000501	0.00454	CcSEcCtD
Vandetanib—Gastritis—Simvastatin—atherosclerosis	0.000499	0.00453	CcSEcCtD
Vandetanib—FLT3—liver—atherosclerosis	0.000497	0.00623	CbGeAlD
Vandetanib—EPHB6—adipose tissue—atherosclerosis	0.000495	0.0062	CbGeAlD
Vandetanib—STK35—liver—atherosclerosis	0.000487	0.0061	CbGeAlD
Vandetanib—KDR—cardiovascular system—atherosclerosis	0.00048	0.00601	CbGeAlD
Vandetanib—MAP2K5—cardiovascular system—atherosclerosis	0.00048	0.00601	CbGeAlD
Vandetanib—YES1—adipose tissue—atherosclerosis	0.000478	0.00599	CbGeAlD
Vandetanib—Pancreatitis—Simvastatin—atherosclerosis	0.000478	0.00433	CcSEcCtD
Vandetanib—PDGFRB—connective tissue—atherosclerosis	0.000477	0.00598	CbGeAlD
Vandetanib—Photosensitivity reaction—Lovastatin—atherosclerosis	0.000476	0.00431	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.000475	0.00431	CcSEcCtD
Vandetanib—ABL2—liver—atherosclerosis	0.000475	0.00595	CbGeAlD
Vandetanib—Dry skin—Niacin—atherosclerosis	0.000475	0.0043	CcSEcCtD
Vandetanib—STK10—adipose tissue—atherosclerosis	0.000474	0.00594	CbGeAlD
Vandetanib—Bronchitis—Simvastatin—atherosclerosis	0.000469	0.00425	CcSEcCtD
Vandetanib—Dry skin—Pravastatin—atherosclerosis	0.000467	0.00424	CcSEcCtD
Vandetanib—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.000466	0.00423	CcSEcCtD
Vandetanib—EGFR—liver—atherosclerosis	0.000463	0.00581	CbGeAlD
Vandetanib—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.000461	0.00418	CcSEcCtD
Vandetanib—SRC—adipose tissue—atherosclerosis	0.00046	0.00577	CbGeAlD
Vandetanib—Nasopharyngitis—Pravastatin—atherosclerosis	0.000456	0.00413	CcSEcCtD
Vandetanib—Infestation NOS—Ezetimibe—atherosclerosis	0.000456	0.00413	CcSEcCtD
Vandetanib—Infestation—Ezetimibe—atherosclerosis	0.000456	0.00413	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000453	0.00411	CcSEcCtD
Vandetanib—FLT4—liver—atherosclerosis	0.000452	0.00566	CbGeAlD
Vandetanib—Urinary tract infection—Lovastatin—atherosclerosis	0.000452	0.0041	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.00045	0.00408	CcSEcCtD
Vandetanib—RIPK2—liver—atherosclerosis	0.000449	0.00563	CbGeAlD
Vandetanib—VEGFA—liver—atherosclerosis	0.000448	0.00561	CbGeAlD
Vandetanib—Influenza—Niacin—atherosclerosis	0.000447	0.00406	CcSEcCtD
Vandetanib—Dysphagia—Niacin—atherosclerosis	0.000447	0.00406	CcSEcCtD
Vandetanib—FMO1—liver—atherosclerosis	0.000446	0.00558	CbGeAlD
Vandetanib—Photosensitivity reaction—Simvastatin—atherosclerosis	0.000445	0.00403	CcSEcCtD
Vandetanib—Influenza—Pravastatin—atherosclerosis	0.000441	0.004	CcSEcCtD
Vandetanib—Arrhythmia—Rosuvastatin—atherosclerosis	0.00044	0.00399	CcSEcCtD
Vandetanib—IRAK4—liver—atherosclerosis	0.000439	0.0055	CbGeAlD
Vandetanib—Sinusitis—Lovastatin—atherosclerosis	0.000436	0.00395	CcSEcCtD
Vandetanib—Depression—Simvastatin—atherosclerosis	0.000433	0.00393	CcSEcCtD
Vandetanib—Pancreatitis—Pravastatin—atherosclerosis	0.000432	0.00392	CcSEcCtD
Vandetanib—Mental disorder—Rosuvastatin—atherosclerosis	0.000431	0.00391	CcSEcCtD
Vandetanib—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000431	0.00391	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.000431	0.00391	CcSEcCtD
Vandetanib—Bronchitis—Niacin—atherosclerosis	0.00043	0.0039	CcSEcCtD
Vandetanib—ERBB3—liver—atherosclerosis	0.00043	0.00539	CbGeAlD
Vandetanib—Sinusitis—Ezetimibe—atherosclerosis	0.000427	0.00388	CcSEcCtD
Vandetanib—ABL1—connective tissue—atherosclerosis	0.000426	0.00533	CbGeAlD
Vandetanib—KDR—adipose tissue—atherosclerosis	0.000423	0.0053	CbGeAlD
Vandetanib—MAP2K5—adipose tissue—atherosclerosis	0.000423	0.0053	CbGeAlD
Vandetanib—PDGFRB—cardiovascular system—atherosclerosis	0.000415	0.00521	CbGeAlD
Vandetanib—Dysuria—Pravastatin—atherosclerosis	0.000412	0.00374	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000409	0.00371	CcSEcCtD
Vandetanib—Sinusitis—Simvastatin—atherosclerosis	0.000408	0.0037	CcSEcCtD
Vandetanib—MKNK1—liver—atherosclerosis	0.000404	0.00506	CbGeAlD
Vandetanib—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000402	0.00365	CcSEcCtD
Vandetanib—LCK—liver—atherosclerosis	0.000399	0.005	CbGeAlD
Vandetanib—FGR—liver—atherosclerosis	0.000399	0.005	CbGeAlD
Vandetanib—Weight decreased—Pravastatin—atherosclerosis	0.000399	0.00362	CcSEcCtD
Vandetanib—AXL—liver—atherosclerosis	0.000397	0.00498	CbGeAlD
Vandetanib—Erythema multiforme—Lovastatin—atherosclerosis	0.000394	0.00358	CcSEcCtD
Vandetanib—Depression—Pravastatin—atherosclerosis	0.000392	0.00355	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000389	0.00353	CcSEcCtD
Vandetanib—Stomatitis—Niacin—atherosclerosis	0.000389	0.00353	CcSEcCtD
Vandetanib—Erythema multiforme—Ezetimibe—atherosclerosis	0.000387	0.00351	CcSEcCtD
Vandetanib—FMO3—liver—atherosclerosis	0.000385	0.00483	CbGeAlD
Vandetanib—SLK—liver—atherosclerosis	0.000382	0.00479	CbGeAlD
Vandetanib—Urinary tract infection—Pravastatin—atherosclerosis	0.000382	0.00346	CcSEcCtD
Vandetanib—Cough—Rosuvastatin—atherosclerosis	0.000374	0.00339	CcSEcCtD
Vandetanib—FYN—liver—atherosclerosis	0.000372	0.00466	CbGeAlD
Vandetanib—Angiopathy—Ezetimibe—atherosclerosis	0.000371	0.00337	CcSEcCtD
Vandetanib—ABL1—cardiovascular system—atherosclerosis	0.00037	0.00464	CbGeAlD
Vandetanib—Erythema multiforme—Simvastatin—atherosclerosis	0.000369	0.00335	CcSEcCtD
Vandetanib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000369	0.00334	CcSEcCtD
Vandetanib—Sinusitis—Pravastatin—atherosclerosis	0.000369	0.00334	CcSEcCtD
Vandetanib—Alopecia—Lovastatin—atherosclerosis	0.000368	0.00334	CcSEcCtD
Vandetanib—PDGFRB—adipose tissue—atherosclerosis	0.000366	0.00459	CbGeAlD
Vandetanib—Arthralgia—Rosuvastatin—atherosclerosis	0.000365	0.00331	CcSEcCtD
Vandetanib—TEK—liver—atherosclerosis	0.000363	0.00455	CbGeAlD
Vandetanib—MAP4K5—liver—atherosclerosis	0.000363	0.00455	CbGeAlD
Vandetanib—Alopecia—Ezetimibe—atherosclerosis	0.000361	0.00328	CcSEcCtD
Vandetanib—Erlotinib—ALB—atherosclerosis	0.000361	0.175	CrCbGaD
Vandetanib—Haemoglobin—Niacin—atherosclerosis	0.00036	0.00327	CcSEcCtD
Vandetanib—Mental disorder—Ezetimibe—atherosclerosis	0.000358	0.00325	CcSEcCtD
Vandetanib—Haemorrhage—Niacin—atherosclerosis	0.000358	0.00325	CcSEcCtD
Vandetanib—Malnutrition—Ezetimibe—atherosclerosis	0.000356	0.00323	CcSEcCtD
Vandetanib—Dysgeusia—Lovastatin—atherosclerosis	0.000355	0.00322	CcSEcCtD
Vandetanib—Muscle spasms—Lovastatin—atherosclerosis	0.000349	0.00317	CcSEcCtD
Vandetanib—Infection—Rosuvastatin—atherosclerosis	0.000347	0.00315	CcSEcCtD
Vandetanib—Visual impairment—Niacin—atherosclerosis	0.000345	0.00313	CcSEcCtD
Vandetanib—Alopecia—Simvastatin—atherosclerosis	0.000345	0.00313	CcSEcCtD
Vandetanib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000343	0.00311	CcSEcCtD
Vandetanib—Muscle spasms—Ezetimibe—atherosclerosis	0.000342	0.00311	CcSEcCtD
Vandetanib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000342	0.0031	CcSEcCtD
Vandetanib—Vision blurred—Lovastatin—atherosclerosis	0.000342	0.0031	CcSEcCtD
Vandetanib—Mental disorder—Simvastatin—atherosclerosis	0.000342	0.0031	CcSEcCtD
Vandetanib—Tremor—Lovastatin—atherosclerosis	0.00034	0.00309	CcSEcCtD
Vandetanib—Visual impairment—Pravastatin—atherosclerosis	0.00034	0.00308	CcSEcCtD
Vandetanib—YES1—liver—atherosclerosis	0.000335	0.0042	CbGeAlD
Vandetanib—Eye disorder—Niacin—atherosclerosis	0.000335	0.00304	CcSEcCtD
Vandetanib—Erythema multiforme—Pravastatin—atherosclerosis	0.000333	0.00302	CcSEcCtD
Vandetanib—Dysgeusia—Simvastatin—atherosclerosis	0.000333	0.00302	CcSEcCtD
Vandetanib—STK10—liver—atherosclerosis	0.000332	0.00417	CbGeAlD
Vandetanib—Cardiac disorder—Pravastatin—atherosclerosis	0.000327	0.00297	CcSEcCtD
Vandetanib—ABL1—adipose tissue—atherosclerosis	0.000327	0.00409	CbGeAlD
Vandetanib—Muscle spasms—Simvastatin—atherosclerosis	0.000326	0.00296	CcSEcCtD
Vandetanib—Angiopathy—Niacin—atherosclerosis	0.000325	0.00295	CcSEcCtD
Vandetanib—SRC—liver—atherosclerosis	0.000323	0.00404	CbGeAlD
Vandetanib—Vision blurred—Simvastatin—atherosclerosis	0.00032	0.0029	CcSEcCtD
Vandetanib—Arrhythmia—Niacin—atherosclerosis	0.00032	0.0029	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000319	0.00289	CcSEcCtD
Vandetanib—Tremor—Simvastatin—atherosclerosis	0.000318	0.00289	CcSEcCtD
Vandetanib—Alopecia—Niacin—atherosclerosis	0.000316	0.00287	CcSEcCtD
Vandetanib—Insomnia—Rosuvastatin—atherosclerosis	0.000316	0.00287	CcSEcCtD
Vandetanib—Arrhythmia—Pravastatin—atherosclerosis	0.000315	0.00286	CcSEcCtD
Vandetanib—Paraesthesia—Rosuvastatin—atherosclerosis	0.000314	0.00285	CcSEcCtD
Vandetanib—Malnutrition—Niacin—atherosclerosis	0.000312	0.00283	CcSEcCtD
Vandetanib—Alopecia—Pravastatin—atherosclerosis	0.000312	0.00283	CcSEcCtD
Vandetanib—Cough—Ezetimibe—atherosclerosis	0.000311	0.00282	CcSEcCtD
Vandetanib—Chest pain—Lovastatin—atherosclerosis	0.000309	0.0028	CcSEcCtD
Vandetanib—Arthralgia—Lovastatin—atherosclerosis	0.000309	0.0028	CcSEcCtD
Vandetanib—Anxiety—Lovastatin—atherosclerosis	0.000308	0.00279	CcSEcCtD
Vandetanib—Dyspepsia—Rosuvastatin—atherosclerosis	0.000308	0.00279	CcSEcCtD
Vandetanib—Hypertension—Ezetimibe—atherosclerosis	0.000307	0.00279	CcSEcCtD
Vandetanib—Chest pain—Ezetimibe—atherosclerosis	0.000303	0.00275	CcSEcCtD
Vandetanib—Arthralgia—Ezetimibe—atherosclerosis	0.000303	0.00275	CcSEcCtD
Vandetanib—Dry mouth—Lovastatin—atherosclerosis	0.000302	0.00274	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000301	0.00273	CcSEcCtD
Vandetanib—Dysgeusia—Pravastatin—atherosclerosis	0.000301	0.00273	CcSEcCtD
Vandetanib—Muscle spasms—Niacin—atherosclerosis	0.0003	0.00272	CcSEcCtD
Vandetanib—Pain—Rosuvastatin—atherosclerosis	0.000299	0.00271	CcSEcCtD
Vandetanib—Constipation—Rosuvastatin—atherosclerosis	0.000299	0.00271	CcSEcCtD
Vandetanib—MAP2K5—liver—atherosclerosis	0.000297	0.00372	CbGeAlD
Vandetanib—KDR—liver—atherosclerosis	0.000297	0.00372	CbGeAlD
Vandetanib—Dry mouth—Ezetimibe—atherosclerosis	0.000296	0.00269	CcSEcCtD
Vandetanib—Muscle spasms—Pravastatin—atherosclerosis	0.000295	0.00268	CcSEcCtD
Vandetanib—Infection—Lovastatin—atherosclerosis	0.000294	0.00267	CcSEcCtD
Vandetanib—Vision blurred—Niacin—atherosclerosis	0.000294	0.00267	CcSEcCtD
Vandetanib—Thrombocytopenia—Lovastatin—atherosclerosis	0.00029	0.00263	CcSEcCtD
Vandetanib—Vision blurred—Pravastatin—atherosclerosis	0.000289	0.00262	CcSEcCtD
Vandetanib—Arthralgia—Simvastatin—atherosclerosis	0.000289	0.00262	CcSEcCtD
Vandetanib—Chest pain—Simvastatin—atherosclerosis	0.000289	0.00262	CcSEcCtD
Vandetanib—Infection—Ezetimibe—atherosclerosis	0.000289	0.00262	CcSEcCtD
Vandetanib—Anxiety—Simvastatin—atherosclerosis	0.000288	0.00261	CcSEcCtD
Vandetanib—Tremor—Pravastatin—atherosclerosis	0.000288	0.00261	CcSEcCtD
Vandetanib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000286	0.00259	CcSEcCtD
Vandetanib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000285	0.00259	CcSEcCtD
Vandetanib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000285	0.00258	CcSEcCtD
Vandetanib—Skin disorder—Ezetimibe—atherosclerosis	0.000282	0.00256	CcSEcCtD
Vandetanib—Oedema—Simvastatin—atherosclerosis	0.000277	0.00251	CcSEcCtD
Vandetanib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000276	0.00251	CcSEcCtD
Vandetanib—Infection—Simvastatin—atherosclerosis	0.000275	0.0025	CcSEcCtD
Vandetanib—Loss of consciousness—Niacin—atherosclerosis	0.000274	0.00249	CcSEcCtD
Vandetanib—Cough—Niacin—atherosclerosis	0.000272	0.00247	CcSEcCtD
Vandetanib—Thrombocytopenia—Simvastatin—atherosclerosis	0.000271	0.00246	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00027	0.00245	CcSEcCtD
Vandetanib—Insomnia—Lovastatin—atherosclerosis	0.000268	0.00243	CcSEcCtD
Vandetanib—Cough—Pravastatin—atherosclerosis	0.000268	0.00243	CcSEcCtD
Vandetanib—Paraesthesia—Lovastatin—atherosclerosis	0.000266	0.00241	CcSEcCtD
Vandetanib—Arthralgia—Niacin—atherosclerosis	0.000265	0.00241	CcSEcCtD
Vandetanib—Hypertension—Pravastatin—atherosclerosis	0.000265	0.0024	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000265	0.0024	CcSEcCtD
Vandetanib—Dyspnoea—Lovastatin—atherosclerosis	0.000264	0.0024	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000264	0.00239	CcSEcCtD
Vandetanib—Insomnia—Ezetimibe—atherosclerosis	0.000263	0.00238	CcSEcCtD
Vandetanib—Chest pain—Pravastatin—atherosclerosis	0.000261	0.00237	CcSEcCtD
Vandetanib—Arthralgia—Pravastatin—atherosclerosis	0.000261	0.00237	CcSEcCtD
Vandetanib—Paraesthesia—Ezetimibe—atherosclerosis	0.000261	0.00237	CcSEcCtD
Vandetanib—Dyspepsia—Lovastatin—atherosclerosis	0.000261	0.00237	CcSEcCtD
Vandetanib—Anxiety—Pravastatin—atherosclerosis	0.00026	0.00236	CcSEcCtD
Vandetanib—Dry mouth—Niacin—atherosclerosis	0.00026	0.00235	CcSEcCtD
Vandetanib—Dyspnoea—Ezetimibe—atherosclerosis	0.000259	0.00235	CcSEcCtD
Vandetanib—Decreased appetite—Lovastatin—atherosclerosis	0.000258	0.00234	CcSEcCtD
Vandetanib—PDGFRB—liver—atherosclerosis	0.000257	0.00322	CbGeAlD
Vandetanib—Dyspepsia—Ezetimibe—atherosclerosis	0.000256	0.00232	CcSEcCtD
Vandetanib—Fatigue—Lovastatin—atherosclerosis	0.000255	0.00232	CcSEcCtD
Vandetanib—Oedema—Niacin—atherosclerosis	0.000254	0.00231	CcSEcCtD
Vandetanib—Pain—Lovastatin—atherosclerosis	0.000253	0.0023	CcSEcCtD
Vandetanib—Constipation—Lovastatin—atherosclerosis	0.000253	0.0023	CcSEcCtD
Vandetanib—Decreased appetite—Ezetimibe—atherosclerosis	0.000253	0.00229	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000252	0.00229	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000251	0.00228	CcSEcCtD
Vandetanib—Asthenia—Rosuvastatin—atherosclerosis	0.000251	0.00228	CcSEcCtD
Vandetanib—Insomnia—Simvastatin—atherosclerosis	0.000251	0.00227	CcSEcCtD
Vandetanib—Oedema—Pravastatin—atherosclerosis	0.000251	0.00227	CcSEcCtD
Vandetanib—Fatigue—Ezetimibe—atherosclerosis	0.000251	0.00227	CcSEcCtD
Vandetanib—Infection—Pravastatin—atherosclerosis	0.000249	0.00226	CcSEcCtD
Vandetanib—Paraesthesia—Simvastatin—atherosclerosis	0.000249	0.00226	CcSEcCtD
Vandetanib—ABCC1—adipose tissue—atherosclerosis	0.000249	0.00312	CbGeAlD
Vandetanib—Pain—Ezetimibe—atherosclerosis	0.000248	0.00225	CcSEcCtD
Vandetanib—Constipation—Ezetimibe—atherosclerosis	0.000248	0.00225	CcSEcCtD
Vandetanib—Pruritus—Rosuvastatin—atherosclerosis	0.000247	0.00224	CcSEcCtD
Vandetanib—Skin disorder—Niacin—atherosclerosis	0.000247	0.00224	CcSEcCtD
Vandetanib—Dyspnoea—Simvastatin—atherosclerosis	0.000247	0.00224	CcSEcCtD
Vandetanib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000245	0.00223	CcSEcCtD
Vandetanib—Dyspepsia—Simvastatin—atherosclerosis	0.000244	0.00221	CcSEcCtD
Vandetanib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000242	0.0022	CcSEcCtD
Vandetanib—ORM1—liver—atherosclerosis	0.000241	0.00302	CbGeAlD
Vandetanib—Decreased appetite—Simvastatin—atherosclerosis	0.000241	0.00219	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000239	0.00217	CcSEcCtD
Vandetanib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000239	0.00217	CcSEcCtD
Vandetanib—Fatigue—Simvastatin—atherosclerosis	0.000239	0.00217	CcSEcCtD
Vandetanib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000238	0.00216	CcSEcCtD
Vandetanib—Pain—Simvastatin—atherosclerosis	0.000237	0.00215	CcSEcCtD
Vandetanib—Constipation—Simvastatin—atherosclerosis	0.000237	0.00215	CcSEcCtD
Vandetanib—Abdominal pain—Lovastatin—atherosclerosis	0.000234	0.00212	CcSEcCtD
Vandetanib—Body temperature increased—Lovastatin—atherosclerosis	0.000234	0.00212	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000232	0.0021	CcSEcCtD
Vandetanib—Dizziness—Rosuvastatin—atherosclerosis	0.000231	0.0021	CcSEcCtD
Vandetanib—Insomnia—Niacin—atherosclerosis	0.00023	0.00209	CcSEcCtD
Vandetanib—Body temperature increased—Ezetimibe—atherosclerosis	0.00023	0.00208	CcSEcCtD
Vandetanib—Abdominal pain—Ezetimibe—atherosclerosis	0.00023	0.00208	CcSEcCtD
Vandetanib—ABL1—liver—atherosclerosis	0.000229	0.00287	CbGeAlD
Vandetanib—Paraesthesia—Niacin—atherosclerosis	0.000228	0.00207	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000228	0.00207	CcSEcCtD
Vandetanib—Dyspnoea—Niacin—atherosclerosis	0.000227	0.00206	CcSEcCtD
Vandetanib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000227	0.00206	CcSEcCtD
Vandetanib—Insomnia—Pravastatin—atherosclerosis	0.000227	0.00206	CcSEcCtD
Vandetanib—Gefitinib—ALB—atherosclerosis	0.000226	0.11	CrCbGaD
Vandetanib—Paraesthesia—Pravastatin—atherosclerosis	0.000225	0.00204	CcSEcCtD
Vandetanib—Dyspepsia—Niacin—atherosclerosis	0.000224	0.00203	CcSEcCtD
Vandetanib—Dyspnoea—Pravastatin—atherosclerosis	0.000223	0.00203	CcSEcCtD
Vandetanib—Decreased appetite—Niacin—atherosclerosis	0.000221	0.00201	CcSEcCtD
Vandetanib—Dyspepsia—Pravastatin—atherosclerosis	0.000221	0.002	CcSEcCtD
Vandetanib—Rash—Rosuvastatin—atherosclerosis	0.00022	0.002	CcSEcCtD
Vandetanib—Dermatitis—Rosuvastatin—atherosclerosis	0.00022	0.002	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Niacin—atherosclerosis	0.00022	0.00199	CcSEcCtD
Vandetanib—Body temperature increased—Simvastatin—atherosclerosis	0.000219	0.00199	CcSEcCtD
Vandetanib—Abdominal pain—Simvastatin—atherosclerosis	0.000219	0.00199	CcSEcCtD
Vandetanib—Headache—Rosuvastatin—atherosclerosis	0.000219	0.00199	CcSEcCtD
Vandetanib—Decreased appetite—Pravastatin—atherosclerosis	0.000218	0.00198	CcSEcCtD
Vandetanib—Pain—Niacin—atherosclerosis	0.000218	0.00197	CcSEcCtD
Vandetanib—Fatigue—Pravastatin—atherosclerosis	0.000216	0.00196	CcSEcCtD
Vandetanib—Pain—Pravastatin—atherosclerosis	0.000214	0.00194	CcSEcCtD
Vandetanib—Constipation—Pravastatin—atherosclerosis	0.000214	0.00194	CcSEcCtD
Vandetanib—Asthenia—Lovastatin—atherosclerosis	0.000213	0.00193	CcSEcCtD
Vandetanib—ALB—liver—atherosclerosis	0.000211	0.00265	CbGeAlD
Vandetanib—Pruritus—Lovastatin—atherosclerosis	0.00021	0.0019	CcSEcCtD
Vandetanib—Asthenia—Ezetimibe—atherosclerosis	0.000208	0.00189	CcSEcCtD
Vandetanib—Gastrointestinal pain—Niacin—atherosclerosis	0.000208	0.00189	CcSEcCtD
Vandetanib—Nausea—Rosuvastatin—atherosclerosis	0.000208	0.00188	CcSEcCtD
Vandetanib—ABCG2—adipose tissue—atherosclerosis	0.000206	0.00258	CbGeAlD
Vandetanib—Pruritus—Ezetimibe—atherosclerosis	0.000206	0.00186	CcSEcCtD
Vandetanib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000205	0.00186	CcSEcCtD
Vandetanib—Diarrhoea—Lovastatin—atherosclerosis	0.000203	0.00184	CcSEcCtD
Vandetanib—Abdominal pain—Niacin—atherosclerosis	0.000201	0.00182	CcSEcCtD
Vandetanib—Body temperature increased—Niacin—atherosclerosis	0.000201	0.00182	CcSEcCtD
Vandetanib—Asthenia—Simvastatin—atherosclerosis	0.000199	0.0018	CcSEcCtD
Vandetanib—Diarrhoea—Ezetimibe—atherosclerosis	0.000199	0.0018	CcSEcCtD
Vandetanib—Body temperature increased—Pravastatin—atherosclerosis	0.000198	0.0018	CcSEcCtD
Vandetanib—Abdominal pain—Pravastatin—atherosclerosis	0.000198	0.0018	CcSEcCtD
Vandetanib—Pruritus—Simvastatin—atherosclerosis	0.000196	0.00178	CcSEcCtD
Vandetanib—Dizziness—Lovastatin—atherosclerosis	0.000196	0.00178	CcSEcCtD
Vandetanib—Dizziness—Ezetimibe—atherosclerosis	0.000192	0.00174	CcSEcCtD
Vandetanib—Diarrhoea—Simvastatin—atherosclerosis	0.00019	0.00172	CcSEcCtD
Vandetanib—Vomiting—Lovastatin—atherosclerosis	0.000188	0.00171	CcSEcCtD
Vandetanib—Rash—Lovastatin—atherosclerosis	0.000187	0.00169	CcSEcCtD
Vandetanib—Dermatitis—Lovastatin—atherosclerosis	0.000187	0.00169	CcSEcCtD
Vandetanib—Headache—Lovastatin—atherosclerosis	0.000186	0.00168	CcSEcCtD
Vandetanib—Vomiting—Ezetimibe—atherosclerosis	0.000185	0.00168	CcSEcCtD
Vandetanib—Dizziness—Simvastatin—atherosclerosis	0.000183	0.00166	CcSEcCtD
Vandetanib—Rash—Ezetimibe—atherosclerosis	0.000183	0.00166	CcSEcCtD
Vandetanib—Dermatitis—Ezetimibe—atherosclerosis	0.000183	0.00166	CcSEcCtD
Vandetanib—Asthenia—Niacin—atherosclerosis	0.000183	0.00166	CcSEcCtD
Vandetanib—Headache—Ezetimibe—atherosclerosis	0.000182	0.00165	CcSEcCtD
Vandetanib—Pruritus—Niacin—atherosclerosis	0.00018	0.00163	CcSEcCtD
Vandetanib—Asthenia—Pravastatin—atherosclerosis	0.00018	0.00163	CcSEcCtD
Vandetanib—Pruritus—Pravastatin—atherosclerosis	0.000177	0.00161	CcSEcCtD
Vandetanib—Vomiting—Simvastatin—atherosclerosis	0.000176	0.0016	CcSEcCtD
Vandetanib—Nausea—Lovastatin—atherosclerosis	0.000176	0.0016	CcSEcCtD
Vandetanib—Rash—Simvastatin—atherosclerosis	0.000175	0.00158	CcSEcCtD
Vandetanib—Dermatitis—Simvastatin—atherosclerosis	0.000175	0.00158	CcSEcCtD
Vandetanib—ABCC1—liver—atherosclerosis	0.000174	0.00219	CbGeAlD
Vandetanib—Diarrhoea—Niacin—atherosclerosis	0.000174	0.00158	CcSEcCtD
Vandetanib—Headache—Simvastatin—atherosclerosis	0.000174	0.00157	CcSEcCtD
Vandetanib—Nausea—Ezetimibe—atherosclerosis	0.000173	0.00157	CcSEcCtD
Vandetanib—Diarrhoea—Pravastatin—atherosclerosis	0.000171	0.00155	CcSEcCtD
Vandetanib—Dizziness—Niacin—atherosclerosis	0.000168	0.00153	CcSEcCtD
Vandetanib—Dizziness—Pravastatin—atherosclerosis	0.000166	0.0015	CcSEcCtD
Vandetanib—Nausea—Simvastatin—atherosclerosis	0.000165	0.00149	CcSEcCtD
Vandetanib—Vomiting—Niacin—atherosclerosis	0.000162	0.00147	CcSEcCtD
Vandetanib—Rash—Niacin—atherosclerosis	0.00016	0.00146	CcSEcCtD
Vandetanib—Dermatitis—Niacin—atherosclerosis	0.00016	0.00145	CcSEcCtD
Vandetanib—Headache—Niacin—atherosclerosis	0.000159	0.00145	CcSEcCtD
Vandetanib—Vomiting—Pravastatin—atherosclerosis	0.000159	0.00145	CcSEcCtD
Vandetanib—Rash—Pravastatin—atherosclerosis	0.000158	0.00143	CcSEcCtD
Vandetanib—Dermatitis—Pravastatin—atherosclerosis	0.000158	0.00143	CcSEcCtD
Vandetanib—Headache—Pravastatin—atherosclerosis	0.000157	0.00142	CcSEcCtD
Vandetanib—Nausea—Niacin—atherosclerosis	0.000151	0.00137	CcSEcCtD
Vandetanib—Nausea—Pravastatin—atherosclerosis	0.000149	0.00135	CcSEcCtD
Vandetanib—ABCG2—liver—atherosclerosis	0.000144	0.00181	CbGeAlD
Vandetanib—CYP3A4—liver—atherosclerosis	0.000101	0.00126	CbGeAlD
Vandetanib—YES1—Signaling Pathways—MAPK8—atherosclerosis	2.18e-06	1.25e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ESR1—atherosclerosis	2.18e-06	1.24e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—NFKB1—atherosclerosis	2.18e-06	1.24e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MAPK3—atherosclerosis	2.17e-06	1.24e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—VEGFA—atherosclerosis	2.17e-06	1.24e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—STAT3—atherosclerosis	2.17e-06	1.24e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LPA—atherosclerosis	2.17e-06	1.24e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—AKT1—atherosclerosis	2.17e-06	1.24e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—MAPK3—atherosclerosis	2.16e-06	1.24e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NOS3—atherosclerosis	2.16e-06	1.24e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL6—atherosclerosis	2.16e-06	1.23e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—F2—atherosclerosis	2.15e-06	1.23e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SERPINE1—atherosclerosis	2.15e-06	1.23e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MAPK8—atherosclerosis	2.14e-06	1.22e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CG—atherosclerosis	2.14e-06	1.22e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NOS3—atherosclerosis	2.13e-06	1.22e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TGFB1—atherosclerosis	2.13e-06	1.22e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—HMOX1—atherosclerosis	2.13e-06	1.22e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PDGFB—atherosclerosis	2.11e-06	1.21e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TGFB1—atherosclerosis	2.11e-06	1.2e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—NFKB1—atherosclerosis	2.1e-06	1.2e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—BGN—atherosclerosis	2.1e-06	1.2e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—AKT1—atherosclerosis	2.09e-06	1.2e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—AKT1—atherosclerosis	2.09e-06	1.2e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—STAT3—atherosclerosis	2.09e-06	1.2e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—AKT1—atherosclerosis	2.09e-06	1.19e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NOS3—atherosclerosis	2.09e-06	1.19e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—AKT1—atherosclerosis	2.08e-06	1.19e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOA5—atherosclerosis	2.08e-06	1.19e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MAPK3—atherosclerosis	2.07e-06	1.18e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ALB—atherosclerosis	2.07e-06	1.18e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—STAT3—atherosclerosis	2.07e-06	1.18e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK8—atherosclerosis	2.06e-06	1.18e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AGT—atherosclerosis	2.06e-06	1.18e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CG—atherosclerosis	2.06e-06	1.18e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—atherosclerosis	2.06e-06	1.18e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—MAPK3—atherosclerosis	2.05e-06	1.17e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NOS3—atherosclerosis	2.05e-06	1.17e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—AKT1—atherosclerosis	2.05e-06	1.17e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—MAPK3—atherosclerosis	2.05e-06	1.17e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOB—atherosclerosis	2.04e-06	1.16e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—INS—atherosclerosis	2.02e-06	1.16e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—LEP—atherosclerosis	2.02e-06	1.15e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APOE—atherosclerosis	2.02e-06	1.15e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—atherosclerosis	2.02e-06	1.15e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TGFB1—atherosclerosis	2.01e-06	1.15e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—AKT1—atherosclerosis	2e-06	1.15e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IL6—atherosclerosis	2e-06	1.14e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CAV1—atherosclerosis	2e-06	1.14e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	2e-06	1.14e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MAPK3—atherosclerosis	2e-06	1.14e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APOA1—atherosclerosis	2e-06	1.14e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—STAT3—atherosclerosis	2e-06	1.14e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TGFB1—atherosclerosis	1.99e-06	1.14e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1B—atherosclerosis	1.99e-06	1.14e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCL2—atherosclerosis	1.99e-06	1.14e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—atherosclerosis	1.99e-06	1.14e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GSTM1—atherosclerosis	1.98e-06	1.13e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—NOS3—atherosclerosis	1.98e-06	1.13e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—atherosclerosis	1.98e-06	1.13e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MAPK3—atherosclerosis	1.97e-06	1.13e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—STAT3—atherosclerosis	1.96e-06	1.12e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF1—atherosclerosis	1.96e-06	1.12e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—INS—atherosclerosis	1.95e-06	1.11e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—LPL—atherosclerosis	1.95e-06	1.11e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—TGFB1—atherosclerosis	1.94e-06	1.11e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.93e-06	1.1e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ESR1—atherosclerosis	1.93e-06	1.1e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL2—atherosclerosis	1.92e-06	1.1e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—STAT3—atherosclerosis	1.92e-06	1.1e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TGFB1—atherosclerosis	1.91e-06	1.09e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MAPK3—atherosclerosis	1.91e-06	1.09e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—F2—atherosclerosis	1.91e-06	1.09e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GPX1—atherosclerosis	1.9e-06	1.09e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL8—atherosclerosis	1.89e-06	1.08e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—STAT3—atherosclerosis	1.89e-06	1.08e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1—atherosclerosis	1.89e-06	1.08e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MAPK3—atherosclerosis	1.87e-06	1.07e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—NFKB1—atherosclerosis	1.86e-06	1.06e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SERPINE1—atherosclerosis	1.86e-06	1.06e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL8—atherosclerosis	1.85e-06	1.06e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TGFB1—atherosclerosis	1.85e-06	1.06e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CD36—atherosclerosis	1.85e-06	1.06e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—atherosclerosis	1.85e-06	1.06e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MAPK3—atherosclerosis	1.83e-06	1.05e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK8—atherosclerosis	1.83e-06	1.04e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CG—atherosclerosis	1.82e-06	1.04e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL8—atherosclerosis	1.82e-06	1.04e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—atherosclerosis	1.81e-06	1.04e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—STAT3—atherosclerosis	1.81e-06	1.03e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK3—atherosclerosis	1.8e-06	1.03e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—atherosclerosis	1.8e-06	1.03e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SERPINE1—atherosclerosis	1.79e-06	1.02e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TGFB1—atherosclerosis	1.78e-06	1.02e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—atherosclerosis	1.77e-06	1.01e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOS3—atherosclerosis	1.77e-06	1.01e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—atherosclerosis	1.75e-06	1e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—STAT3—atherosclerosis	1.74e-06	9.95e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.73e-06	9.9e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MAPK3—atherosclerosis	1.73e-06	9.87e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—INS—atherosclerosis	1.73e-06	9.86e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LIPC—atherosclerosis	1.72e-06	9.84e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARA—atherosclerosis	1.72e-06	9.82e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOC3—atherosclerosis	1.71e-06	9.78e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOS3—atherosclerosis	1.71e-06	9.77e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—atherosclerosis	1.71e-06	9.77e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LDLR—atherosclerosis	1.7e-06	9.72e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL2—atherosclerosis	1.7e-06	9.7e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NFKB1—atherosclerosis	1.69e-06	9.66e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—atherosclerosis	1.68e-06	9.57e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—atherosclerosis	1.67e-06	9.56e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—atherosclerosis	1.67e-06	9.54e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1—atherosclerosis	1.67e-06	9.54e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AGT—atherosclerosis	1.66e-06	9.51e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK3—atherosclerosis	1.66e-06	9.51e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK8—atherosclerosis	1.66e-06	9.5e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—atherosclerosis	1.66e-06	9.49e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CETP—atherosclerosis	1.66e-06	9.49e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NFKB1—atherosclerosis	1.66e-06	9.46e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—atherosclerosis	1.65e-06	9.41e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—atherosclerosis	1.65e-06	9.41e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—atherosclerosis	1.64e-06	9.38e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOE—atherosclerosis	1.63e-06	9.32e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NFKB1—atherosclerosis	1.63e-06	9.31e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK8—atherosclerosis	1.63e-06	9.3e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CAV1—atherosclerosis	1.62e-06	9.24e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—atherosclerosis	1.61e-06	9.23e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOA1—atherosclerosis	1.61e-06	9.22e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—atherosclerosis	1.61e-06	9.19e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—atherosclerosis	1.61e-06	9.17e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK8—atherosclerosis	1.6e-06	9.16e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—atherosclerosis	1.6e-06	9.14e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK3—atherosclerosis	1.6e-06	9.12e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.59e-06	9.09e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—atherosclerosis	1.59e-06	9.07e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SERPINE1—atherosclerosis	1.59e-06	9.06e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—atherosclerosis	1.58e-06	9.04e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—atherosclerosis	1.57e-06	8.99e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—atherosclerosis	1.54e-06	8.81e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—atherosclerosis	1.53e-06	8.77e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—atherosclerosis	1.52e-06	8.68e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—atherosclerosis	1.52e-06	8.68e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—atherosclerosis	1.52e-06	8.67e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—atherosclerosis	1.52e-06	8.66e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—atherosclerosis	1.51e-06	8.66e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—atherosclerosis	1.51e-06	8.65e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—atherosclerosis	1.5e-06	8.59e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.5e-06	8.58e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—atherosclerosis	1.5e-06	8.55e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—atherosclerosis	1.49e-06	8.5e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—atherosclerosis	1.48e-06	8.47e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—atherosclerosis	1.48e-06	8.46e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—atherosclerosis	1.48e-06	8.45e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—atherosclerosis	1.48e-06	8.43e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK3—atherosclerosis	1.47e-06	8.42e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CG—atherosclerosis	1.47e-06	8.41e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—atherosclerosis	1.46e-06	8.37e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—atherosclerosis	1.46e-06	8.37e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—atherosclerosis	1.46e-06	8.35e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—atherosclerosis	1.46e-06	8.34e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK3—atherosclerosis	1.45e-06	8.3e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—atherosclerosis	1.44e-06	8.25e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—atherosclerosis	1.43e-06	8.17e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—atherosclerosis	1.42e-06	8.13e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK3—atherosclerosis	1.42e-06	8.12e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—atherosclerosis	1.42e-06	8.12e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—atherosclerosis	1.41e-06	8.05e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NFKB1—atherosclerosis	1.41e-06	8.05e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK3—atherosclerosis	1.4e-06	8e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—atherosclerosis	1.4e-06	7.99e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—atherosclerosis	1.39e-06	7.96e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—INS—atherosclerosis	1.39e-06	7.96e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—atherosclerosis	1.39e-06	7.92e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK8—atherosclerosis	1.38e-06	7.91e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—atherosclerosis	1.38e-06	7.89e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—atherosclerosis	1.38e-06	7.88e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—atherosclerosis	1.37e-06	7.84e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—atherosclerosis	1.37e-06	7.81e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—atherosclerosis	1.36e-06	7.76e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NFKB1—atherosclerosis	1.36e-06	7.76e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—atherosclerosis	1.35e-06	7.7e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—atherosclerosis	1.34e-06	7.67e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—atherosclerosis	1.34e-06	7.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.34e-06	7.65e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK8—atherosclerosis	1.33e-06	7.62e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—atherosclerosis	1.33e-06	7.61e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—atherosclerosis	1.32e-06	7.53e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—atherosclerosis	1.29e-06	7.35e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—atherosclerosis	1.28e-06	7.3e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—atherosclerosis	1.27e-06	7.23e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—atherosclerosis	1.26e-06	7.21e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—atherosclerosis	1.26e-06	7.21e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—atherosclerosis	1.24e-06	7.06e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—atherosclerosis	1.23e-06	7.04e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—atherosclerosis	1.22e-06	6.98e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—atherosclerosis	1.22e-06	6.97e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—atherosclerosis	1.22e-06	6.95e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—atherosclerosis	1.22e-06	6.95e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—atherosclerosis	1.21e-06	6.94e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK3—atherosclerosis	1.21e-06	6.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NFKB1—atherosclerosis	1.2e-06	6.87e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK8—atherosclerosis	1.18e-06	6.75e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—atherosclerosis	1.17e-06	6.7e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—atherosclerosis	1.17e-06	6.67e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK3—atherosclerosis	1.17e-06	6.66e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—atherosclerosis	1.16e-06	6.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.15e-06	6.56e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—atherosclerosis	1.13e-06	6.46e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—atherosclerosis	1.12e-06	6.41e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—atherosclerosis	1.12e-06	6.39e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOB—atherosclerosis	1.1e-06	6.29e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—atherosclerosis	1.09e-06	6.23e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—atherosclerosis	1.08e-06	6.17e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—atherosclerosis	1.08e-06	6.15e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—atherosclerosis	1.08e-06	6.15e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.07e-06	6.12e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—atherosclerosis	1.06e-06	6.07e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LPL—atherosclerosis	1.05e-06	6e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—atherosclerosis	1.04e-06	5.94e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—atherosclerosis	1.03e-06	5.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK3—atherosclerosis	1.03e-06	5.89e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GPX1—atherosclerosis	1.02e-06	5.86e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—atherosclerosis	1.02e-06	5.85e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—atherosclerosis	1e-06	5.72e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CD36—atherosclerosis	9.98e-07	5.7e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—atherosclerosis	9.93e-07	5.68e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—atherosclerosis	9.79e-07	5.6e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—atherosclerosis	9.59e-07	5.48e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—atherosclerosis	9.46e-07	5.41e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—atherosclerosis	9.44e-07	5.39e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARA—atherosclerosis	9.28e-07	5.3e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—atherosclerosis	9.1e-07	5.2e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AGT—atherosclerosis	8.99e-07	5.14e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—atherosclerosis	8.84e-07	5.05e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOE—atherosclerosis	8.81e-07	5.03e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAV1—atherosclerosis	8.72e-07	4.99e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOA1—atherosclerosis	8.7e-07	4.97e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—atherosclerosis	8.52e-07	4.87e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—atherosclerosis	8.15e-07	4.66e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	7.95e-07	4.54e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—atherosclerosis	7.86e-07	4.49e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—atherosclerosis	7.67e-07	4.38e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—atherosclerosis	7.54e-07	4.31e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—INS—atherosclerosis	7.52e-07	4.3e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—atherosclerosis	6.96e-07	3.98e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—atherosclerosis	6.9e-07	3.94e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—atherosclerosis	6.6e-07	3.77e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—atherosclerosis	6.03e-07	3.45e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—atherosclerosis	5.62e-07	3.21e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—atherosclerosis	3.03e-07	1.73e-06	CbGpPWpGaD
